Evaluation of the effectiveness of cabozantinib alone in the treatment of liver cancer

Cabozantinib, as a multi-target tyrosine kinase inhibitor, has demonstrated its therapeutic effect in a variety of solid tumors, especially in the treatment of liver cancer. According to relevant studies, the survival time of patients with advanced liver cancer treated with cabozantinib is significantly prolonged. Specifically, these patients' risk of death fell by 37%. This data provides strong evidence of the effectiveness of cabozantinib in the treatment of liver cancer.

The disease control rate of cabozantinib in the treatment of liver cancer is as high as66%, which means that most patients’ conditions are effectively controlled after using cabozantinib. At the same time, its objective effective rate is approximately 5%. Although this ratio may not seem high, such an effective rate is still clinically significant in the treatment of advanced liver cancer.

The median progression-free survival of liver cancer patients treated with cabozantinib reached 11.2 months. This data further confirms the effectiveness of cabozantinib in extending survival of patients with liver cancer.

In the CELESTIAL study, cabozantinib achieved positive results compared with placebo in the second-line / third-line treatment of patients with advanced hepatocellular carcinoma. Specifically, the overall survival (OS) of patients treated with cabozantinib was 10.2 months, which was longer than the 8.0 months in the control group. In terms of progression-free survival (PFS), the advantages of cabozantinib are even more obvious, which are 5.2 months and 1.9 months respectively.

It is worth mentioning that cabozantinib is particularly effective in controlling bone metastasis. This is an important therapeutic advantage for many liver cancer patients, as bone metastasis is one of the common complications of liver cancer.